A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment.

Liu, Aijun; Yang, Guangzhong; Geng, Chuanying; Wang, Huijuan; Li, Lihong; Li, Yanchen; Wu, Yin; Tian, Ying; Leng, Yun; Wang, Guorong; Gao, Wen; Chen, Wenming

To analyze the effects of bortezomib on the prognosis of the newly diagnosed multiple myeloma patients with renal impairment, we assessed the outcomes of 134 multiple myeloma patients with renal impairment (serum creatinine ≥ 178 μmol/l) who were treated at Beijing Chaoyang Hospital. The patients were divided into two groups: bortezomib (n = 83) and nonbortezomib (n = 51). The overall response rate of the bortezomib group was higher than that of the nonbortezomib group. There was no significant difference in the time to restore renal function, but the complete renal response ratio was significantly higher in the bortezomib group. The 2-year overall survival (OS) rate of the bortezomib group was significantly greater than the nonbortezomib group, as was the 3-year OS rate. Kaplan-Meier analysis revealed significantly better survival for the bortezomib group. The main side effects in the bortezomib group were thrombocytopenia, peripheral neuropathy, infection, and herpes zoster, and there was a low incidence of grades 3 and 4 adverse events. Our findings indicate that bortezomib-based combination chemotherapy can improve the prognosis of the newly diagnosed multiple myeloma patients with renal impairment and should be considered as a first-line therapy.

MULTIPLE myeloma; BORTEZOMIB; B cell lymphoma; MONOCLONAL gammopathies; ANTINEOPLASTIC agents; KAPLAN-Meier estimator

Acta Haematologica, 2016, Vol 135, Issue 3, p140

0001-5792

Academic Journal

10.1159/000440935